Ribociclib (CAS 1211441-98-3): A Comprehensive Product Introduction

Ribociclib, with the CAS number 1211441-98-3, is a significant compound in the field of pharmaceuticals and medical research. This article aims to provide a detailed introduction to Ribociclib, including its properties, uses, applications in various fields, and preparation methods.

I. Product Overview

Ribociclib is a small – molecule inhibitor of cyclin – dependent kinases (CDKs) 4 and 6. These kinases play a crucial role in regulating the cell cycle, and abnormal activation of CDKs 4 and 6 is often associated with the development and progression of various cancers. By inhibiting CDKs 4 and 6, Ribociclib can block the cell cycle progression at the G1 – S checkpoint, thereby preventing the proliferation of cancer cells.

II. Physical and Chemical Properties

1. **Chemical Formula**: The chemical formula of Ribociclib is \(C_{23}H_{27}N_{7}O_{3}\). This formula indicates the specific combination of carbon, hydrogen, nitrogen, and oxygen atoms in the molecule, which is fundamental to its chemical reactivity and biological activity. 2. **Molecular Weight**: Its molecular weight is approximately 449.5 g/mol. The molecular weight affects various physical properties such as solubility and melting point. 3. **Appearance**: Ribociclib usually appears as a white to off – white powder. This physical appearance is important for its identification and handling in the laboratory and pharmaceutical manufacturing processes. 4. **Solubility**: It has limited solubility in water but is more soluble in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol. The solubility characteristics are crucial for formulating it into different pharmaceutical dosage forms.

III. Uses and Applications

1. **Cancer Treatment** – **Breast Cancer**: Ribociclib is primarily used in the treatment of hormone – receptor – positive (HR+), human epidermal growth factor receptor 2 – negative (HER2 -) advanced or metastatic breast cancer. In combination with an aromatase inhibitor, it has shown significant improvement in progression – free survival (PFS) compared to the use of an aromatase inhibitor alone. Clinical trials have demonstrated that the addition of Ribociclib to endocrine therapy can delay the progression of the disease and improve the quality of life for patients. – **Other Cancers**: There is also ongoing research exploring the potential of Ribociclib in the treatment of other types of cancers, such as endometrial cancer and non – small cell lung cancer. The inhibition of CDKs 4 and 6 may be effective in blocking the growth and spread of cancer cells in these malignancies as well. 2. **Medical Research** – **Cell Cycle Studies**: Ribociclib is a valuable tool in cell cycle research. Scientists can use it to study the role of CDKs 4 and 6 in normal and abnormal cell division. By treating cells with Ribociclib, they can observe the changes in the cell cycle progression and understand the molecular mechanisms underlying cell proliferation. – **Drug Development**: It also serves as a reference compound in the development of new CDK inhibitors. Pharmaceutical companies can compare the efficacy and safety of new compounds with Ribociclib to identify more potent and selective CDK inhibitors for cancer treatment.

IV. Preparation Methods

1. **Synthetic Routes** – The synthesis of Ribociclib typically involves a series of chemical reactions starting from commercially available starting materials. One common approach begins with the synthesis of key intermediate compounds through condensation, cyclization, and substitution reactions. – For example, the synthesis may start with the reaction of an appropriate amine with a carboxylic acid derivative to form an amide bond. Then, further cyclization reactions are carried out to form the characteristic heterocyclic rings of Ribociclib. – During the synthesis process, strict control of reaction conditions such as temperature, pressure, and reaction time is required to ensure high yields and purity of the final product. Purification steps such as column chromatography and recrystallization are often used to obtain pure Ribociclib. 2. **Quality Control in Preparation** – In the preparation of Ribociclib, quality control is of utmost importance. Analytical techniques such as high – performance liquid chromatography (HPLC) are used to determine the purity of the product. Mass spectrometry can be used to confirm the molecular structure of Ribociclib. – Additionally, strict compliance with Good Manufacturing Practices (GMP) is necessary to ensure the safety and efficacy of the final product for pharmaceutical use.

V. Safety and Side Effects

1. **Common Side Effects** – When used in cancer treatment, Ribociclib may cause some side effects. Common side effects include neutropenia (a decrease in the number of neutrophils, a type of white blood cell), nausea, fatigue, diarrhea, and hair loss. Neutropenia is a particularly important side effect as it can increase the risk of infections in patients. 2. **Precautions** – Patients taking Ribociclib need to have regular blood tests to monitor their blood cell counts. Healthcare providers should closely monitor patients for any signs of side effects and adjust the dosage or treatment plan accordingly. – Ribociclib may also interact with other medications, so it is important for patients to inform their doctors about all the medications they are taking.

VI. Market and Regulatory Status

1. **Market Availability** – Ribociclib is available in the market under the brand name Kisqali. It is marketed by Novartis, a leading pharmaceutical company. The drug has been approved for use in many countries, including the United States, European Union member states, and Japan. 2. **Regulatory Approval** – The approval of Ribociclib by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is based on extensive clinical trials demonstrating its safety and efficacy in cancer treatment. These regulatory approvals ensure that the drug meets the high standards of quality, safety, and effectiveness required for pharmaceutical products.

VII. Future Perspectives

1. **Combination Therapies** – There is great potential for developing new combination therapies using Ribociclib. For example, combining Ribociclib with other targeted therapies or immunotherapies may further improve the treatment outcomes for cancer patients. Research is ongoing to explore the optimal combinations and dosing regimens. 2. **Expansion of Indications** – As more research is conducted, Ribociclib may be approved for the treatment of other types of cancers or used in earlier stages of cancer. This could significantly expand its clinical applications and benefit more patients.

VIII. References

• Author 1. Title of Article 1. Journal Name 1, Volume, Pages, Year.
• Author 2. Title of Article 2. Journal Name 2, Volume, Pages, Year.
• Author 3. Title of Article 3. Journal Name 3, Volume, Pages, Year.

IX. Inquiry Form